Pathophysiology of Portal Hypertension
Portal hypertension develops when increased intrahepatic vascular resistance combines with elevated portal blood flow, following the hydraulic principle where Pressure = Resistance × Flow 1.
Primary Mechanism: Increased Intrahepatic Resistance
The fundamental cause of portal hypertension is progressive elevation of intrahepatic vascular resistance due to both structural (fixed) and functional (dynamic) components within the liver sinusoids 1.
Fixed Structural Components
The irreversible architectural changes include:
- Fibrosis and regenerative nodules that physically distort hepatic architecture
- Larger bands of fibrosis creating mechanical obstruction
- Sinusoidal fibrosis narrowing vascular channels
- Intrahepatic shunts disrupting normal blood flow patterns 1
Dynamic Functional Components
The reversible elements involve:
- Activated hepatic stellate cells (HSCs) that contract and alter sinusoidal blood flow—this is the key cellular mediator of increased resistance 1, 2
- Hepatocyte swelling further compressing sinusoidal spaces
- Liver sinusoidal endothelial cell (LSEC) dysfunction impairing normal vasodilation 2, 3
- Microvascular thrombosis within hepatic sinusoids 2, 3
Secondary Mechanism: Hyperdynamic Circulation
As portal pressure rises, compensatory splanchnic vasodilation occurs, paradoxically increasing portal blood flow and further elevating portal pressure 1. This creates a vicious cycle where both resistance and flow contribute to worsening portal hypertension.
Anatomic Levels of Obstruction
The site of increased resistance varies by disease etiology and can occur at:
- Presinusoidal level (e.g., schistosomiasis, non-cirrhotic portal fibrosis)
- Sinusoidal level (most common in cirrhosis from any cause)
- Postsinusoidal level (e.g., Budd-Chiari syndrome, sinusoidal obstruction syndrome) 1, 4
Clinical Thresholds
Portal hypertension exists when hepatic venous pressure gradient (HVPG) exceeds 5 mm Hg, but clinically significant portal hypertension (CSPH) is defined as HVPG ≥10 mm Hg—this threshold predicts development of varices, ascites, hepatic encephalopathy, and mortality 1. An HVPG ≥16 mm Hg is strongly associated with death 1.
Molecular and Cellular Mechanisms
At the cellular level, portal hypertension involves:
- Cellular and molecular derangement progressing over time in intrahepatic sinusoids
- Hepatic stellate cell activation as the central pathogenic event—these cells transition from quiescent to contractile phenotype
- Pathological angiogenesis developing as disease progresses
- Vascular hypocontractility in splanchnic vessels contributing to hyperdynamic circulation 1, 5, 6
Important Clinical Caveat
Not all patients with elevated portal pressure develop the same complications—for example, esophageal varices typically require HVPG of 10-12 mm Hg but don't develop in all patients at this threshold due to individual variability in collateral formation and other vascular factors 1. This explains why portal pressure measurement remains superior to surrogate markers like variceal size for risk stratification.